Therapeutics News

WAILEA, Hawaii ― At Hawaiian Eye 2018, Mark Baum, CEO of Imprimis Pharmaceuticals, discusses regulatory challenges facing compounding pharmacies and ways his company and others would like to work with physicians to bring changes to those hurdles.

The FDA approved Bausch + Lomb’s Lumify as the first over-the-counter eye drop developed with low-dose brimonidine tartrate for the treatment of ocular redness.

Patients with moderate-to-severe dry eye reported improvement in some clinical signs and symptoms after using Visaid 0.3% during a 1-month management period, compared to no improvements after the use of 0.9% NaCl solution.

Researchers found in two randomized, double-masked clinical trials that once-daily dosing of netarsudil 0.02% was well tolerated for the treatment of ocular hypertension and open-angle glaucoma and non-inferior to timolol.

The use of a cryopreserved amniotic membrane in dry eye disease correlated with corneal nerve regeneration as evidenced by a significant increase in corneal nerve density and corneal sensitivity, according to a study presented at the American Academy of Ophthalmology meeting.

The FDA granted orphan drug designation to IVMED-80, an eye drop used for cross-linking the cornea to treat keratoconus.

The Massachusetts Society of Optometrists is working with practitioners, residents and state legislators to ensure its optometric scope of practice is in line with the rest of the country, according to Matthew Forgues, OD, president of the Massachusetts Society of Optometrists, in an interview with Primary Care Optometry News.

The combined use of silicone hydrogel contact lenses with autologous serum eye drops can treat postinfectious corneal persistent epithelial defects and prevent continuous corneal melting during acute disease, according to researchers.

The FDA has approved the new drug application for the once-daily glaucoma treatment Vyzulta, according to a press release issued jointly by Bausch + Lomb, a subsidiary of Valeant Pharmaceuticals, and Nicox S.A.

The AOA will cooperate and assist federal agencies to fight the epidemic of opioid abuse nationwide and support the safe expansion of access to essential health care services, according to a statement from the group.